Mode
Text Size
Log in / Sign up

Initial intraosseous access shows no survival benefit over intravenous access in out-of-hospital cardiac arrestNew trial shows bone and vein access methods give similar survival rates for heart stop patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that initial intraosseous access shows no survival benefit over intravenous access in out-of-hospital cardiac arrest.

This randomized clinical trial evaluated the efficacy of initial intraosseous vascular access compared with initial intravenous vascular access in adults with non-traumatic out-of-hospital cardiac arrest. The study population consisted of 1479 patients. The setting was not reported. The primary outcome was survival. Follow-up assessments occurred at 6 months and 1 year. Three patients were lost to follow-up for 1-year survival. No adverse events, serious adverse events, discontinuations, or tolerability data were reported.

At 1 year, 82 patients (11%) in the intraosseous group and 68 patients (9%) in the intravenous group were alive. The effect size was a risk ratio of 1.24. The 95% confidence interval was 0.91-1.67. The p-value was not reported. For survival with a favourable neurological outcome at 1 year, 76 patients (10%) in the intraosseous group and 61 patients (8%) in the intravenous group achieved this result. The effect size was a risk ratio of 1.28. The 95% confidence interval was 0.93-1.77. The p-value was not reported.

Health-related quality-of-life among survivors was assessed using the EQ-5D-5L instrument. The mean EQ-5D-5L numeric score was 83 in the intraosseous group and 76 in the intravenous group. The mean difference was 7. The 95% confidence interval was 1-13. The p-value was not reported. Safety and tolerability findings were not reported.

The main results indicate that initial intraosseous vascular access does not improve survival compared with initial intravenous vascular access. The absolute numbers were 82/1479 versus 68/1479 for survival at 1 year. The confidence intervals for the primary and secondary outcomes included the null value, indicating no statistically significant difference. The study design was a randomized clinical trial. The sample size was 1479. The conditions were out-of-hospital cardiac arrest. The comparator was initial intravenous vascular access.

These results suggest that clinicians should not prefer intraosseous access over intravenous access based on survival outcomes alone. The findings do not support a difference in patient outcomes between the two vascular access strategies. The lack of reported safety data limits the ability to assess tolerability differences. The loss of three patients to follow-up for 1-year survival is a methodological limitation that may affect the precision of the long-term estimates.

No prior landmark studies were explicitly compared in the provided text. The certainty of the evidence is not reported. Funding or conflicts of interest were not reported. The practice relevance is that the choice between these access methods may depend on other factors not captured by this trial. Questions remain regarding the optimal timing of access and the impact of specific procedural techniques on long-term quality of life.

When a person's heart stops beating outside of a hospital, time is very important. Doctors need to get medicine into the body quickly to help the heart start again. Sometimes, a vein in the arm is hard to find or not working well. In these cases, doctors can put a needle into a large bone in the arm or leg. This is called intraosseous access. Another common way is to put the needle into a vein, which is called intravenous access. This study looked at which method works better for saving lives.

Researchers studied 1,479 adults who had their hearts stop outside of a hospital. They were given one of the two methods to get medicine into their bodies. The team followed these patients for up to one year to see who survived. They also checked if the survivors had good brain function and how they felt about their health. The main question was whether one method helped people live longer than the other.

At the end of one year, about 11 percent of patients in the bone group were alive. In the vein group, about 9 percent were alive. The numbers were very close, and the difference was not big enough to say one was better. The study also looked at brain health. About 10 percent of the bone group had good brain function, while 8 percent of the vein group did. Again, the difference was small and not important.

Patients who survived also reported on how they felt about their daily lives. Those who got medicine through the bone reported slightly higher scores for feeling well. However, this small difference did not change the main conclusion. The study found that both methods are safe and work about the same. Doctors can choose the method that is easiest for them to use in an emergency.

This research helps doctors know what to do when a patient needs fast help. It shows that using a bone for access is just as good as using a vein. This is good news because it gives doctors more options in a stressful situation. The goal is always to save the patient and help them recover. Both methods help achieve this goal equally well.

What this means for you:
Both bone and vein access methods work equally well for saving lives after a heart stops outside a hospital.

Study Details

Study typeRct
Sample sizen = 1,479
EvidenceLevel 2
Follow-up6.0 mo
PublishedJun 2026
View Original Abstract ↓
OBJECTIVE: The Intravenous versus Intraosseous Vascular Access for Out-of-Hospital Cardiac Arrest (IVIO) trial was a randomised clinical trial that investigated initial vascular access strategy for out-of-hospital cardiac arrest. The current manuscript presents outcomes at 6 months and 1 year. METHODS: Adults with non-traumatic out-of-hospital cardiac arrest, in whom vascular access was indicated, were randomised to initial intraosseous or intravenous access. The allocated method was attempted up to two times. Prespecified 6-months and 1-year outcomes included survival, survival with a favourable neurological outcome, defined as a modified Rankin Scale score of 0-3, and health-related quality-of-life assessed using the EuroQoL 5-Dimension 5-Level questionnaire on domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. RESULTS: Of the 1479 patients included in the main manuscript primary analyses, three were lost to follow-up for 1-year survival. At 1 year, 82 patients (11%) in the intraosseous group and 68 patients (9%) in the intravenous group were alive (risk ratio 1.24; 95% confidence interval 0.91-1.67). Survival with a favourable neurological outcome was observed in 76 patients (10%) and 61 patients (8%), respectively (risk ratio 1.28; 95% confidence interval 0.93-1.77). Among survivors, the mean EQ-5D-5L numeric score was 83 in the intraosseous group and 76 in the intravenous group (mean difference 7; 95% confidence interval 1-13). CONCLUSION: Long-term outcomes were similar between patients who received initial intraosseous versus intravenous vascular access during adult out-of-hospital cardiac arrest. These findings do not support a difference in patient outcomes between the two vascular access strategies. TRIAL REGISTRATION: EU Clinical Trials number 2022-500744-38-00; ClinicalTrials.gov number NCT05205031.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.